The presence of receptors for the steroid hormone oestrogen (ER) divides breast cancer into two groups with different biological and clinical characteristics; the ER +ve subset is associated with a longer relapse-free survival (McGuire et al., 1986 ) when stage II patients or postmenopausal women are considered. Other factors such as progesterone receptors (McGuire et al., 1986) , thymidine labelling index (Silvestrini et al., 1984) and S-phase fraction (McGuire & Dressler 1985) , may predict disease-free survival. Recently the epidermal growth factor receptor (EGF-R) was shown to be positively associated with high grade, ER -ve carcinomas and has been suggested as an additional cell marker to further segregate prognostically relevant breast cancer subsets (Sainsbury et al., 1987) .
We extended the search for biologically relevant markers in breast cancer and focused on two unrelated cell components of putative interest, the p53 protein and the cytoskeletal protein vimentin, after an extensive screening of several well characterized and new monoclonal antibodies.
p53 is a transformation-associated protein which has been included in the group of nuclear oncogenes because of its ability to immortalize normal cells and transform them in cooperation with a mutated oncogene (Eliyahu et al., 1984) . Vimentin, a class III intermediate filament (IF) , is distributed on all mesenchymal cells and is coexpressed with other intermediate filaments on an increasing variety of epithelial tumours (Gould, 1985) . Its presence on breast cancer cells was first described in pleural malignant effusions (Ramaekers et al., 1983) .
The function of vimentin is still unknown, but according to tentative explanation (Traub, 1985) , vimentin is a nucleic acid-binding protein, regulated through a Ca+ + dependent proteinase, which is stored as polymerized filaments in the cytoplasm. The DNA-binding sequences of vimentin are analogous to the homologous region of the steroid hormone receptors (Traub, 1985) .
In this study we show that p53, vimentin and EGF-R are expressed in Er -ve All primary antibodies were used at saturating concentration after careful titration on appropriate targets and counterlabelled by indirect immunoalkaline phosphatase or immunoperoxidase methods as previously described (Cattoretti et al., 1988 
Immunohistochemistry
Immunohistochemical evaluation was performed on 4 jum thick frozen sections placed on clean glass slides and fixed in acetone or 10% buffered formaline (ER-ICA).
EGF-R and vimentin were considered positive when 10% or more of the tumour cells were stained. P53 and ER-ICA staining were considered positive when neoplastic cells exhibited unambiguous nuclear staining irrespective of the percentage of the positive cells. PAb421 antibody weakly cross-reacts with cytoplasmic cytokeratins and therefore nuclear staining only was evaluated (Cattoretti et al., 1988) .
Oestrogen ( Bloom and Richardson (1957) .
Results
The analysis of 196 primary breast cancer specimens for p53, vimentin (VIM) and EGF-R showed that 15.8%, 25% and 34.2% respectively were positive with the appropriate antibody on tumour cells (Table I) .
p53 ( EGF-R was revealed by an exclusive membrane positivity ( Figure 1c ) and was homogeneously expressed on the totality of the tumour cells in most specimens.
The immunohistochemical ER staining (ER-ICA) was found on the nucleus of neoplastic cells and also in residual normal breast ductal cells; tumour heterogeneity was observed even though clearly negative and positive cases could be identified (see also DiFronzo et al., 1986) .
p53, VIM and EGF-R were distributed preferentially on ER-ICA -ve carcinomas (Table I) .
As expected, p53, VIM and EGF-R reactivity largely (but not completely) overlapped on ER -ve specimens: 40/91 tumours found positive with one marker displayed an additional one or two antigens (Table II) (Table III) . In 9 cases (4.59%) none of the determinants was expressed.
Oestrogen and/or progesterone receptors, determined biochemically, were significantly lower on p53 +ve (ER and PgR) and EGF-R +ve (PgR) carcinomas (Table IV) (Ramaekers et al., 1983) (Schmid et al., 1983) . Cells grown in hormonedepleted sera expressed vimentin IF whereas they did not when supplemented culture medium was added (Schmid et al., 1983) . It is not therefore unexpected to find the phenotypic traits of an exogenously hormone-deprived cell in a tumour that lacks the appropriate hormone receptor. Experimental evidence that VIM is selectively expressed in hormone-independent, oncogene-transformed epithelial cell lines has been recently reported (Agnor et al., 1987) . The vimentin gene was cloned from serum stimulated hamster fibroblasts (Rittling et al., 1986) and expression was shown to be regulated at the transcriptional level be serum- derived growth factors such as PDGF, but not EGF, insulin or platelet-poor plasma (Ferrari et al., 1986) . Vimentin and the myc gene are induced with similar kinetics in early G1 phase (Rittling et al., 1986) .
p53, which has been included on the nuclear oncogene family because of its biological transforming activity (Eliyahu et al., 1984) , bears no homology with known protooncogenes; however, it resembles another gene (myc) as far as its transforming strength, subcellular location and activation kinetics in in vitro models are concerned (Bienz et al., 1984) . By contrast with myc and vimentin, the p53 gene is maximally expressed in the mid G1 cell cycle phase (Rittling et al., 1986) . p53 may be a regulatory element for the induction or maintenance of replicative DNA synthesis (Braithwaite et al., 1987; Mercer et al., 1982) . p53 is readily expressed after mitogen stimulation of normal cells in vitro (Mercer & Baserga, 1985) , but not on resting cells, nor was it detectable on various normal tissues, including breast and mammary dysplasia (Cattoretti et al., 1988) . The presence of EGF-R has already been shown to be associated with large, high-grade, ER -ve breast carcinomas (Sainsbury et al., 1987) . EGF-R is at the same time the receptor for a natural mitogen on epithelial cells (Taketani & Oka, 1983 ) and the cellular homologue of the viral oncogene erb-B (Downward et al., 1984) . Several pieces of experimental evidence indicate that the inverse relationship found between ER on the one hand and p53, VIM and EGF-R on the other, has some basis in the proliferative status of the tumour cell; breast cancer progenitor cells in culture lack ER (Kodama et al., 1985) and rapidly proliferating cells accumulate a low amount of the receptor (Jakesz et al., 1984) . p 53 itself has been found to parallel the RNA content of cycling cells and the p53 intracellular content rises when the cell proceeds to the Glb-G2 phase (Darzynkiewicz et al., 1986) . p53 +ve carcinomas display significantly higher reactivity with the proliferation associated Ki-67 MAb and express a higher amount of the transferrin receptor (Cattoretti et al., 1988) . Similarly, the median percentage of S-phase cells is higher in tumours lacking both ER and PgR (McGuire et al., 1986; McGuire & Dressler, 1985) .
In addition, the presence of EGF-R may indicate the ability of the cell to be stimulated by natural mitogens such as EGF or TGFa, the latter also being able to partially replace the tumour promoting effect of oestrogen (Dickson et al., 1986) . The presence of EGF-R immunoreactivity has also been positively related to a high S-phase content of breast cancer (Walker & Camplejohn, 1986) . We can thus speculate that the presence of either one of p53, VIM or EGF-R is an indicator of an actively cycling tumour cell with a reduced amount of ER or a diminished requirement of ER to grow. Approximately half of the breast cancer specimens found positive for one marker were positive for another one or two, but all the possible combinations were represented as outlined in Table II . The large spectrum of phenotypes observed can be explained in two ways: either minimal amounts of the apparently negative cell marker could not be detected in some cases because of the limited sensitivity of the technique employed; or because the genes involved depend on coincident, but not identical, stimuli to be expressed and therefore the membrane phenotype is indeed heterogeneous. Although we are aware of the limitations of the very sensitive techniques we used,~ye favour the latter explanation. There is experimental evidence that myc and p53 respond differently to EGF (Filmus et al, 1987) , phytohemagglutinin and interleukin 2 (IL2) stimulation (Reed et al., 1986) . However, both are expressed in cycling cells together with the IL2 receptor and both are necessary for IL2-induced growth (Reed et al., 1986) . Vimentin, in contrast to myc, responds to PDGF but not to EGF.
There is also evidence that a tumour cell with a given growth factor receptor repertoire may produce multiple growth factors, even those for which it has no membrane receptors ; furthermore, not all tumour cell lines produce the same variety of growth factors (Peres et al., 1987) . If we assume that p53 and vimentin depend on two separate combinations of growth factors and receptors to be induced, then it is conceivable that coexpression of both in tumour cells reflects the frequent but not obligate coexistence of several autocrine pathways.
Despite all the caveats outlined above, we identified two well characterized proteins which definitely indicate the cellular phenotype of an ER negative breast carcinoma and thus may facilitate the search for the appropriate growth factors and receptors.
Whether the combined expression of EGF-R, vimentin and p53 contributes a growth advantage to the tumour causing a more aggressive, hormone-independent proliferation of a given carcinoma must still be determined by in vitro and ad hoc clinical studies. 
